Previously Aired - May 19, 2020 Worldwide, almost 297,000 cases of brain and nervous system tumors are diagnosed per year.1 Glioblastoma is the most common and aggressive type of malignant primary brain tumor, with a median survival of 10-12 months.2,3 Treatment for GBM typically involves surgical removal, followed by radiation therapy or chemotherapy. There has been recent interest in intraoperative radiotherapy (IORT) as a potential treatment option for effective local tumor control. This approach is conceptually appealing because IORT allows for the delivery of a large, localized radiation dose to the tumor bed and the micro- and macroscopic tumor remnants in the vicinity of the surgical cavity. The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body. Learn more about the promising preliminary results of this procedure after GBM relapse. Join Professor Krivoshapkin & Dr. Gaytan for an informative product showcase discussing Neuro IORT and the benefits it offers to physicians, facilities and patients. References:
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!
Ut enim ad minima veniam, quis nostrum exercitationem ullam!